(Q44451228)

English

Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials

scientific article published in June 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

multicenter clinical trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

L Mauriac

1

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

J E Pippen

2

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

J Quaresma Albano

3

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

S Z Gertler

4

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

C K Osborne

5

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

publication date

1 June 2003

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

European Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

39

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

1228-1233

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Use of tamoxifen for breast cancer: twenty-eight years later

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900199-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Biologic basis and evolving role of aromatase inhibitors in the management of invasive carcinoma of the breast

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900199-0

7 January 2021

based on heuristic

inferred from DOI database lookup

The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900199-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900199-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900199-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2803%2900199-0

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0959-8049(03)00199-0

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44451228&oldid=2024509665"